Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.38 |
| ▸ | BACE1 | P56817 | 8/20 | 0.38 |
| ▸ | CTSD | P07339 | 2/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32690541 | 0.96 | FOLH1 (0.36) | FOLH1OPRM1OPRD1OPRK1BACE1 | |
| SCHEMBL30811115 | 0.95 | FOLH1 (0.42) | FOLH1OPRM1OPRD1OPRK1BACE1 | |
| SCHEMBL30811111 | 0.92 | FOLH1 (0.38) | FOLH1OPRM1OPRD1OPRK1 | |
| SCHEMBL32690531 | 0.92 | DPP8 (0.41) | OPRM1OPRD1OPRK1 | |
| SCHEMBL30811155 | 0.91 | CPB2 (0.36) | FOLH1OPRM1OPRD1OPRK1 | |
| SCHEMBL32690591 | 0.89 | FOLH1 (0.40) | FOLH1OPRM1OPRD1OPRK1 | |
| SCHEMBL32690539 | 0.89 | IL23R (0.36) | OPRM1OPRD1OPRK1 | |
| SCHEMBL30811137 | 0.88 | PDF (0.38) | OPRM1OPRD1OPRK1 | |
| SCHEMBL32690482 | 0.88 | NPY4R (0.40) | FOLH1 | |
| SCHEMBL30811179 | 0.88 | IL23R (0.41) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | FOLH1 2/4885OPRM1 899/4885OPRD1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.